New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
12:14 EDTMMSI, HSPMerit Medical recalls kits containing previously recalled Hospira product
Merit Medical Systems (MMSI) recalled Custom Procedural Trays/Kits manufactured from April 29, 2013 through August 20, 2013 due to the fact they contained Hospira (HSP) supplied 1% Lidocaine HCl, according to a posting to the FDA's website. The recall notice points out that Hospira previously announced on December 23, 2013 that it had initiated a voluntary nationwide recall to the user level for one lot of Lidocaine HCl Injection due to a reddish orange particulate on the inner surface and floating in the solution. Reference Link
News For MMSI;HSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 4, 2015
08:26 EDTHSPMorgan Stanley to hold a conference
Subscribe for More Information
April 28, 2015
07:33 EDTHSPHospira will not provide annual projections given merger agreement with Pfizer
07:33 EDTHSPHospira expects merger agreement with Pfizer to be completed in 2H15
Subscribe for More Information
07:32 EDTHSPHospira reports Q1 adjusted EPS 97c, consensus 53c
Subscribe for More Information
April 27, 2015
14:41 EDTHSPEarnings Watch: Pfizer up over 6% since its last earnings report
Subscribe for More Information
April 24, 2015
09:36 EDTMMSIMerit Medical upgraded to Outperform from Market Perform at Barrington
Subscribe for More Information
05:43 EDTHSPHospira announces new white paper extrapolation
Hospira announced the publication of a pivotal white paper titled, "Why extrapolation is paramount to achieving the full promise of biosimilars." The white paper highlights the significance of extrapolation in the development of a successful and sustainable biosimilars market. Real-world cost savings and increased patient access to life-saving medicines can be achieved by conducting only scientifically necessary clinical trials, it states, while also calling for more regulatory agencies to adopt the principle of extrapolation. In the white paper, Ramachandra notes that the scientific principle for extrapolation has already been adopted by the European Medicines Agency, or EMA, and that the European Commission, or EC, has approved 21 biosimilar medicines in Europe, including the first biosimilar monoclonal antibody, Inflectra, in September 2013. In addition, the FDA utilized extrapolation to approve the first biosimilar in the United States, biosimilar filgrastim, last month for all the therapeutic indications of the reference product that were available at that time.
April 23, 2015
16:05 EDTMMSIMerit Medical reports Q1 EPS 18c, consensus 15c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use